Hologic (NASDAQ:HOLX) Receives Neutral Rating from BTIG Research

Key Points

• Hologic's stock received a neutral rating from BTIG Research, with analysts highlighting a consensus rating of Moderate Buy and a price target of $80.15.
• The company's stock increased by 3.2% to $74.17, with a significant trading volume of 12.9 million shares compared to its average of 2.7 million.
• Hologic reported quarterly earnings of $1.08 per share, surpassing analyst estimates and indicating a year-over-year revenue growth of 1.2%.

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "neutral" rating reaffirmed by stock analysts at BTIG Research in a note issued to investors on Tuesday,Benzinga reports.

Other equities analysts have also recently issued reports about the stock. Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. Stephens reiterated an "overweight" rating and issued a $78.00 target price on shares of Hologic in a research report on Thursday, September 18th. Argus boosted their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Evercore ISI set a $78.00 target price on shares of Hologic and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Finally, Morgan Stanley increased their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Hologic has a consensus rating of "Moderate Buy" and a consensus price target of $80.15.

Hologic Trading Up 3.2%

Hologic stock traded up $2.30 during mid-day trading on Tuesday, hitting $74.17. The company's stock had a trading volume of 12,978,419 shares, compared to its average volume of 2,662,760. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock's fifty day moving average is $67.19 and its two-hundred day moving average is $63.62. Hologic has a 1 year low of $51.90 and a 1 year high of $84.39. The firm has a market capitalization of $16.50 billion, a PE ratio of 30.79, a price-to-earnings-growth ratio of 2.40 and a beta of 0.63.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the firm earned $1.06 earnings per share. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts anticipate that Hologic will post 4.28 EPS for the current year.

Insider Buying and Selling

In other news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.88% of the company's stock.

Hedge Funds Weigh In On Hologic

Large investors have recently modified their holdings of the stock. Chung Wu Investment Group LLC bought a new position in shares of Hologic during the 2nd quarter worth $26,000. Caitong International Asset Management Co. Ltd raised its stake in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 273 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in Hologic in the 2nd quarter valued at $33,000. Zions Bancorporation National Association UT purchased a new position in shares of Hologic during the 1st quarter worth approximately $34,000. Finally, Cromwell Holdings LLC boosted its holdings in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 436 shares during the period. Institutional investors own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.